Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Systemic Lupus Eryhtematosus (What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe?) | Physician & Payer Forum | EU5 | 2014
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
Systemic Lupus Erythematosus | Treatment Algorithms | Claims Data Analysis | US | 2014
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems, manifesting at various levels of severity, and involving periods of remission and relapse. The…
What Market Access Challenges and Opportunities Lie Ahead for Emerging SLE Biologics? | Physician & Payer Forum | EU5 | 2014
Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…